Compounds > tomoxiprole
Page last updated: 2024-12-11

tomoxiprole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6917745
CHEMBL ID347043
SCHEMBL ID525023
MeSH IDM0127284

Synonyms (21)

Synonym
mdl-035
tomoxiprole
tomoxiprolum [latin]
brn 5975068
tomoxiprole [inn]
2-(4-methoxyphenyl)-3-(1-methylethyl)-3h-naphth(1,2-d)imidazole
3h-naphth(1,2-d)imidazole, 2-(4-methoxyphenyl)-3-(1-methylethyl)-
tomoxiprol [spanish]
3-isopropyl-2-(p-methoxyphenyl)-3h-naphth(1,2-d)imidazole
CHEMBL347043
2-(4-methoxyphenyl)-3-propan-2-ylbenzo[e]benzimidazole
tomoxiprolum
ez948t2878 ,
unii-ez948t2878
76145-76-1
SCHEMBL525023
3-(1-methylethyl)-2-(4-methoxyphenyl)-3h-naphth[1,2-d]imidazole
3-isopropyl-2-(4-methoxyphenyl)-3h-naphtho[1,2-d]imidazole
mdl 035
Q27277446
DTXSID201032783

Research Excerpts

Overview

Tomoxiprole is a nonsteroidal anti-inflammatory compound. It was reported to have low ulcerogenic potential.

ExcerptReferenceRelevance
"Tomoxiprole is a nonsteroidal anti-inflammatory compound that was reported to have low ulcerogenic potential, a quality that would be expected of a cyclooxygenase-2-selective inhibitor, and, in fact, we find it is selective for this isozyme. "( Tomoxiprole selectively inhibits cyclooxygenase-2.
Billah, MM; Carruthers, NI; Egan, RW; She, HS; West, RE; Williams, SM, 1997)		3.18

Bioavailability

ExcerptReferenceRelevance
" A metabolic first pass reduced the extent of oral bioavailability of the parent compound to about half, while absorption (total 14C data) was estimated to be complete."( Pharmacokinetics and metabolism of tomoxiprole, a new analgesic antiinflammatory agent, in the rat.
Assandri, A; Bernareggi, A; Perazzi, A; Ripamonti, A; Toja, E, )		0.41
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID184783Peroral dose showing lethal effects in 50% of the rats with carrageenan -induced paw edema1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
AID170950Compound was evaluated for its antiinflammatory activity by adjuvant-induced polyarthritis test in rats at a dosage of 100 mg/kg administered orally1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
AID196877Compound was evaluated for its gastroulcerogenic effect in rats at a peroral dose of 200 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
AID170141Compound was evaluated for its antipyretic activity by antipyresis effect in comparison with that of Aspirin.1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
AID194099Antiinflammatory activity was measured as the percentage inhibition of edema in carrageenan induced rat paw after peroral administration of 100 mg/kg of compound1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
AID187055Compound was evaluated for its antiinflammatory activity by adjuvant-induced polyarthritis test in rats at a dosage of 100 mg/kg administered orally1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
AID170140Compound was evaluated for its analgesic activity by Randall-Selitto test in comparison with that of Aspirine1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
AID182166Compound was evaluated for its antiinflammatory activity by adjuvant-induced polyarthritis test in rats at a dosage of 100 mg/kg administered orally1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
AID194278Compound was evaluated for its antiinflammatory activity in the cotton pellet induced granuloma(CPG) in normal rats at the dose 200 mg/kg p.o.1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
AID183669Antiinflammatory activity measured as the percentage inhibition of edema in carrageenan induced rat paw after peroral administration of 200 mg/kg of compound1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		2.3720benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.3720aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
letrozole
[no description available]		2.3110nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		1.9610pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		1.9610methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		1.9610icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		1.9610prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
6-ketoprostaglandin f1 alpha
6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.		1.9610prostaglandins Falphahuman metabolite;
mouse metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Adjuvant Arthritis
[description not available]		02.3720
Anasarca
[description not available]		01.9610
Granulomas
[description not available]		01.9610
Ache
[description not available]		01.9610
Gastric Ulcer
[description not available]		02.3720
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		01.9610
Granuloma
A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.		01.9610
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		01.9610
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		02.3720
Breast Cancer
[description not available]		02.3110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.3110
Innate Inflammatory Response
[description not available]		01.9610
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		01.9610
Gastroduodenal Ulcer
[description not available]		01.9610
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		01.9610
Peptic Ulcer
Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		01.9610